|
|
| (35 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | {| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center |
| | | |valign=top| |
| {{Rivaroxaban}} | | |+ |
| | | ! style="background: #4479BA; color:#FFF; width: 100px;" | |
| {{CMG}}; {{AE}} {{AZ}}
| | ! style="background: #4479BA; color:#FFF; width: 200px;" | |
| | | ! style="background: #4479BA; color:#FFF; width: 250px;" | |
| '''''For patient information, click <u>[[Rivaroxaban (patient information)|here]]'''''</u>.
| | |- |
| {{SB}} XARELTO<sup>®</sup>
| | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | |
| | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| ==Overview== | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| '''Rivaroxaban''' (BAY 59-7939) is an [[route of administration|oral]] [[anticoagulant]] invented and manufactured by [[Bayer]]; in a number of countries it is marketed as '''Xarelto'''.<ref name="Xarelto SPC">{{cite web |url=http://www.xarelto.com/scripts/pages/en/information-on-xarelto/summary_of_product_characteristics/index.php |title=Xarelto: Summary of Product Characteristics |publisher=Bayer Schering Pharma AG |year=2008 |accessdate=2009-02-11}}</ref> In the United States, it is marketed by [[Janssen Pharmaceutica]].<ref name="US Approval">{{cite press release |title=FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery |publisher=[[Janssen Pharmaceutica]] |date=2011-07-01 |url=http://m.prnewswire.com/news-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery-124872829.html |accessdate=2011-07-01}}</ref> It is an orally active [[direct factor Xa inhibitor]]. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
| | |} |
| | |
| ==Category== | |
| Direct [[Xa factor]] inhibitor.
| |
| | |
| ==FDA Package Insert==
| |
| === XARELTO®===
| |
| '''| [[Rivaroxaban indications and usage|Indications and Usage]]'''
| |
| '''| [[Rivaroxaban dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Rivaroxaban dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Rivaroxaban contraindications|Contraindications]]'''
| |
| '''| [[Rivaroxaban warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Rivaroxaban adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Rivaroxaban drug interactions|Drug Interactions]]'''
| |
| '''| [[Rivaroxaban use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Rivaroxaban overdosage|Overdosage]]'''
| |
| '''| [[Rivaroxaban description|Description]]'''
| |
| '''| [[Rivaroxaban clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Rivaroxaban nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Rivaroxaban clinical studies|Clinical Studies]]'''
| |
| '''| [[Rivaroxaban how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Rivaroxaban patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Rivaroxaban labels and packages|Labels and Packages]]'''
| |
| | |
| [[image:riva1.png|800px]]
| |
| ==Mechanism of Action==
| |
| XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |